SELENOW: A Promising Drug Target and Biomarker for Diseases (G6415)

Target Name: SELENOW

NCBI ID: G6415

SELENOW

SELENOW: A Promising Drug Target and Biomarker for Diseases

SELENOW (Selenoprotein W) is a protein that is expressed in high levels in the liver and other organs of the body. It is a key regulator of cellular processes in the liver, including the detoxification of harmful substances and the regulation of inflammation. SELENOW has also been shown to play a role in the development and progression of various diseases, including liver cancer, and is Therefore, it is a promising drug target and a potential biomarker for several diseases.

SELENOW is a transmembrane protein that is expressed in various tissues and organs, including the liver, spleen, and pancreas. It is a glycoprotein that consists of a protein core and a transmembrane region. The protein core consists of four domains, including an N-terminus, a catalytic domain, a transmembrane region, and a C-terminus. The transmembrane region is responsible for the protein's unique structure and function.

SELENOW plays a key role in the regulation of cellular processes in the liver. The liver is responsible for filtering out harmful substances from the blood and eliminating them through the feces. SELENOW is involved in this process by helping to detoxify harmful substances and regulate the levels of these substances in the liver.

In addition to its role in detoxification, SELENOW has also been shown to play a key role in the regulation of inflammation. The liver is a major site of inflammation in the body, and SELENOW is involved in regulating the levels of pro-inflammatory enzymes in the liver. This helps to prevent chronic inflammation, which can lead to a range of diseases, including liver cancer.

SELENOW has also been shown to be involved in the development and progression of various diseases, including liver cancer. Studies have shown that high levels of SELENOW are associated with an increased risk of developing liver cancer. Additionally, SELENOW has also been shown to be involved in the regulation of signaling pathways that are important for the development of cancer.

SELENOW is also a potential biomarker for several diseases. Its levels can be easily measured and are not affected by factors such as age, gender, or lifestyle, making it an attractive candidate for use as a biomarker. Additionally, because SELENOW is expressed in a variety of tissues and organs, it can be used as a potential diagnostic marker for a range of diseases.

In conclusion, SELENOW is a protein that plays a key role in the regulation of cellular processes in the liver and has been shown to be involved in the detoxification of harmful substances, the regulation of inflammation, and the development and progression of various diseases, including liver cancer. Its unique structure and function make it an attractive candidate for use as a drug target and a potential biomarker for several diseases. Further research is needed to fully understand the role of SELENOW in these processes and to develop effective treatments for the diseases it is involved in.

Protein Name: Selenoprotein W

Functions: Plays a role as a glutathione (GSH)-dependent antioxidant. May be involved in a redox-related process. May play a role in the myopathies of selenium deficiency (By similarity)

The "SELENOW Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SELENOW comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets